Abstract:Background: Rearranged during transfection (RET) proto-oncogene encodes a receptor tyrosine kinase for glial cell line-derived neurotrophic factor (GDNF) signaling, and high RET expression is closely related to the tumorigenesis and malignancy of neuroblastoma(NB).Methods: We have investigated whether RET signals through hedgehog (HH) pathway in NB cell proliferation and tumor growth by in vitro cell culture and in vivo xenograft approaches.Results: The key members of both GDNF/RET and HH/GLI pathways are expressed in NB cell lines to different extents. Knockdown of RET in NB cells significantly attenuates the activity of HH signaling, whereas overexpression of RET robustly enhances the output of transcriptional activation by HH. Likewise, activation of RET by GDNF induces HH signaling, whereas knockdown of RET attenuates both basal and GDNF-induced activities of HH signaling. Moreover, protein kinase B lies on the downstream of GDNF/RET signaling module to inhibit the GSK3 beta, resulting in activation of HH signaling. Furthermore, either knockdown of RET by shRNA or inhibition of HH pathway by cyclopamine attenuates not only basal but also GDNF-induced proliferation of SH-SY5Y cells, and knockdown of either RET or smoothened in SH-SY5Y cell xenografts significantly attenuated the tumor growth. Finally, inhibition of HH signaling by all and GLI2 inhibitor, Gant61, reduces not only basal but also RET-induced proliferation of SH-SY5Y cells and outgrowth of xenografts.Conclusion: GDNF/RET/AKT/GSK3 beta signaling module activates HH pathway to stimulate NB cells proliferation and tumor outgrowth.3General significance: Targeting HH pathway is a rational approach for therapeutic intervention of NB with high RET expression. (C) 2016 Elsevier B.V. All rights reserved.

Supplementary Figure 1 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Supplementary Figure 4 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Supplementary Methods and Figure Legend from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Supplementary Figure 3 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Supplementary Figure 2 from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Data from NLRR1 Enhances EGF-Mediated <i>MYCN</i> Induction in Neuroblastoma and Accelerates Tumor Growth <i>In Vivo</i>

Nlrr1 Enhances Egf-Mediated Mycn Induction In Neuroblastoma And Accelerates Tumor Growth In Vivo

Supplementary Figure 1 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 2 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure 5 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure 6 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

NLRR1 is a Potential Therapeutic Target in Neuroblastoma and MYCN-Driven Malignant Cancers

Supplementary Figure 4 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure 3 from Neuropilin-1 Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure 1 from ERBB3/HER2 Signaling Promotes Resistance to EGFR Blockade in Head and Neck and Colorectal Cancer Models

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

Supplementary Figure 7 from <i>Neuropilin-1</i> Stimulates Tumor Growth by Increasing Fibronectin Fibril Assembly in the Tumor Microenvironment

Supplementary Figure S6 A-F from Drugging MYCN Oncogenic Signaling Through the MYCN-PA2G4 Binding Interface

Supplementary Figure 6 from HIC1 Silencing in Triple-Negative Breast Cancer Drives Progression Through Misregulation of LCN2

Supplementary Figure 1 from NLRR1 Enhances EGF-Mediated &lt;i&gt;MYCN&lt;/i&gt; Induction in Neuroblastoma and Accelerates Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 4 from NLRR1 Enhances EGF-Mediated &lt;i&gt;MYCN&lt;/i&gt; Induction in Neuroblastoma and Accelerates Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Methods and Figure Legend from NLRR1 Enhances EGF-Mediated &lt;i&gt;MYCN&lt;/i&gt; Induction in Neuroblastoma and Accelerates Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 3 from NLRR1 Enhances EGF-Mediated &lt;i&gt;MYCN&lt;/i&gt; Induction in Neuroblastoma and Accelerates Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;

Supplementary Figure 2 from NLRR1 Enhances EGF-Mediated &lt;i&gt;MYCN&lt;/i&gt; Induction in Neuroblastoma and Accelerates Tumor Growth &lt;i&gt;In Vivo&lt;/i&gt;